The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective and disease-modifying therapies (DMTs), says data and analytics company GlobalData in an overview of ongoing PD research..
With current treatments largely focused on motor symptoms, the pipeline across the seven major markets (7MM) highlights a growing emphasis on DMTs and non-motor symptom therapies, according to GlobalData.